• Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022

    Source: Nasdaq GlobeNewswire / 22 Nov 2022 06:05:00   America/Chicago

    ALPHARETTA, Ga., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that management will participate in the following conferences in November and December 2022:

    BTIG Ophthalmology Day
    Fireside Chat
    Tuesday, November 29, 2022 at 10:30 a.m. ET

    Piper Sandler 34th Annual Healthcare Conference
    Corporate Presentation
    Thursday, December 1, 2022 at 9:50 a.m. ET

    Ophthalmology Innovation Summit (OIS) XII
    Panel Discussion: Spotlight on Gene & Cell Therapy
    Retina Innovation Showcase: Corporate Presentation
    Saturday, December 3, 2022

    Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference
    Ophthalmology Panel Discussion: Take A Look At What's In Store For Wet AMD & Related Diabetic Eye Diseases
    Thursday, December 8, 2022 at 2:45 p.m. ET

    A link to the live and archived webcasts may be accessed on the Clearside website under the Investors section: Events and Presentations.

    About Clearside Biomedical

    Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, is commercially available in the U.S. For more information, please visit www.clearsidebio.com.

    Investor and Media Contacts:

    Jenny Kobin
    Remy Bernarda
    ir@clearsidebio.com
    (678) 430-8206

    Source: Clearside Biomedical, Inc.


    Primary Logo

Share on,